Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein

Cristaudo, Alfonso; Foddis, Rudy; Bonotti, Alessandra; Simonini, Silvia; Vivaldi, Agnese; Guglielmi, Giovanni; Bruno, Rossella; Landi, Debora; Gemignani, Federica; Landi, Stefano
April 2010
Occupational & Environmental Medicine;Apr2010, Vol. 67 Issue 4, p7
Academic Journal
Background Serum mesothelin, also known as soluble mesothelin-related protein (SMRP), reportedly shows increased levels in epithelial-type malignant pleural mesothelioma, but sometimes also arrives at high values in healthy asbestos-exposed subjects. Objectives This study aimed to investigate whether single nucleotide polymorphisms in the 3'untranslated region (3'UTR) of the mesothelin-encoded gene (MSLN) are associated with the SMRP levels measured in serum. Methods The 3'UTR of the mesothelin gene was genotyped in 59 healthy asbestos-exposed subjects, selected on the basis of their SMRP levels. Direct sequencing did not show any new polymorphism, but enabled us to genotype two known SNPs (rs1057147, rs57272256). Differences in the mean values of SMRP in wild-type and variant heterozygote groups were calculated. Results High levels of SMRP in healthy asbestos-exposed subjects were significantly associated with polymorphism rs1057147 (G


Related Articles

  • BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. Hmeljak, Julija; Erčulj, Nina; Dolžan, Vita; Kern, Izidor; Cör, Andrej // Journal of Cancer Research & Clinical Oncology;Nov2011, Vol. 137 Issue 11, p1641 

    Purpose: Malignant pleural mesothelioma is an incurable, asbestos-associated cancer. Its incidence is rapidly increasing and survival remains short. Apoptosis deregulation is an important feature of cancer and survivin, a member of the inhibitor-of-apoptosis-protein family encoded by the BIRC5...

  • NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy. Borelli, Violetta; Moura, Ronal R.; Trevisan, Elisa; Crovella, Sergio // Infectious Agents & Cancer;Aug2015, Vol. 10 Issue 1, p1 

    NRLP1 (rs12150220, rs9889625, rs9900356, rs6502867, rs2670660) and NLRP3 (rs35829419, rs10754558) polymorphisms have been analyzed in 69 subjects with documented asbestos exposure and death for malignant pleural mesothelioma and 59 patients with documented asbestos exposure but death for other...

  • Mesothelioma: cases associated with non-occupational and low dose exposures. Hillerdal, G. // Occupational & Environmental Medicine;Aug1999, Vol. 56 Issue 8, p505 

    Estimates the importance of low dose exposure to asbestos on the risk of mesothelioma. Relativity between the risk of mesothelioma and non-occupational and low dose exposures.

  • Environmental Malignant Mesothelioma in Southern Anatolia: A Study of Fifty Cases. Zeren, E. Handan; Gumurdulu, Derya; Roggli, Victor L.; Tuncer, IIhan; Zorludemir, Suzan; Erkis, Melek // Environmental Health Perspectives;Nov2000, Vol. 108 Issue 11, p1047 

    Examines fifty cases of malignant mesothelioma caused by asbestos exposure in southern Turkey. Details of the clinical and pathologic features of the cases; Involvement of actinolites and tremolites on the development of mesothelioma.

  • Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Magnani, C; Agudo, A; González, C A; Andrion, A; Calleja, A; Chellini, E; Dalmasso, P; Escolar, A; Hernandez, S; Ivaldi, C; Mirabelli, D; Ramirez, J; Turuguet, D; Usel, M; Terracini, B // British Journal of Cancer;7/1/2000, Vol. 83 Issue 1, p104 

    Insufficient evidence exists on the risk of pleural mesothelioma from non-occupational exposure to asbestos. A population-based case-control study was carried out in six areas from Italy, Spain and Switzerland. Information was collected for 215 new histologically confirmed cases and 448...

  • Pleural Mesothelioma with No Asbestos Exposure: A Case Report. BATAHAR, SALMA AIT; OURADI, OTHMANE; ELIDRISSI, SAFAE; AMRO, LAMYAE // Journal of Clinical & Diagnostic Research;Nov2016, Vol. 10 Issue 11, p7 

    Malignant Pleural Mesothelioma (MPM) is the primary malignant tumour of the pleura. It is highly aggressive and linked to the exposure to asbestos fibers. The prognosis of this cancer is bad with a median of survival around 12 months. The diagnosis of pleural mesothelioma is often done at an...

  • Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels. Pass, Harvey I.; Lott, Dan; Lonardo, Fulvio; Harbut, Michael; Liu, Zhandong; Tang, Naimei; Carbone, Michele; Webb, Craig; Wali, Anil // New England Journal of Medicine;10/13/2005, Vol. 353 Issue 15, p1564 

    Background: We investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who...

  • Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure†. Watzka, Stefan B.; Posch, Florian; Pass, Harvey I.; Flores, Raja M.; Hannigan, Gregory E.; Bernhard, David; Weber, Michael; Mueller, Michael R. // European Journal of Cardio-Thoracic Surgery;May2013, Vol. 43 Issue 5, p940 

    OBJECTIVES Integrin-linked kinase (ILK) is an intracellular protein implicated in chronic inflammation and neoplastic transformation. In a recently accomplished pilot study, we showed that ILK can be detected in the serum of patients with benign and malignant chest diseases, including malignant...

  • EphB4 as a therapeutic target in mesothelioma. Ren Liu; Ferguson, Benjamin D.; Yue Zhou; Naga, Kranthi; Salgia, Ravi; Gill, Parkash S.; Krasnoperov, Valery; Liu, Ren; Zhou, Yue // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Malignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos. Current best therapy produces a response in only half of patients, and the median survival with this therapy remains under a year. A search for novel targets and therapeutics is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics